Understand the source comparison
Cardiogen vs Established Cardiac Peptide Biology (Honest Context)
To evaluate Cardiogen fairly, it helps to see what a well-validated cardiac peptide story looks like — and how different its evidence base is. This section is deliberately kept separate from Cardiogen’s own claims. Nothing here is evidence for Cardiogen; it is
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- To evaluate Cardiogen fairly, it helps to see what a well-validated cardiac peptide story looks like — and how different its evidence base is. This section is deliberately kept separate from Cardiogen’s own claims. Nothing here is evidence for Cardiogen; it is context.
- The heart’s natural peptide hormones — atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) — are among the best-characterized signaling molecules in cardiovascular medicine. They act through membrane guanylyl-cyclase receptors (NPR-A and NPR-B) to raise intracellular cyclic GMP, driving natriuresis, vasodilation, and anti-hypertrophic signaling; the receptor biology has been dissected down to the level of specific activating mutations and their effects on catalysis.[10] Clinically, BNP and its precursor fragment NT-proBNP are validated, guideline-endorsed biomarkers used to diagnose and risk-stratify heart failure and valvular disease, and to monitor rehabilitation.[9][11]
- Origin
- Endogenous cardiac hormones
- Synthetic ultrashort peptide
- 22–32 residues
- 3–4 residues
- Defined receptor
- Yes (NPR-A / NPR-B, guanylyl cyclase)
- None established
- Signaling pathway
- Well-mapped (cGMP)
- Proposed nuclear/gene-expression (unvalidated)
- Clinical validation
- Extensive (biomarkers, drug targets)
- None (no RCTs)
- Regulatory footprint
- Approved diagnostics; neprilysin-inhibitor drugs act on this axis
- Not approved anywhere as a drug
- The contrast is the point. Established cardiac-peptide biology rests on identified receptors, reproducible signaling, and large independent clinical datasets. Cardiogen rests on a tissue-specificity hypothesis, computational binding models, and preclinical assays from one research lineage. Both can be discussed intelligently; only one is validated. Presenting Cardiogen as if it shared the natriuretic peptides’ evidentiary standing would be a category error.